Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Alaunos Therapeutics (TCRT) Return on Equity (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Return on Equity for 15 consecutive years, with 1.26% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Equity rose 244.0% year-over-year to 1.26%, compared with a TTM value of 1.26% through Sep 2025, up 244.0%, and an annual FY2024 reading of 1.15%, up 46.0% over the prior year.
  • Return on Equity was 1.26% for Q3 2025 at Alaunos Therapeutics, up from 1.71% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.86% in Q1 2021 and bottomed at 4.94% in Q1 2024.
  • Average Return on Equity over 5 years is 2.02%, with a median of 1.34% recorded in 2021.
  • The sharpest move saw Return on Equity tumbled -379bps in 2024, then soared 285bps in 2025.
  • Year by year, Return on Equity stood at 1.24% in 2021, then rose by 13bps to 1.08% in 2022, then tumbled by -231bps to 3.59% in 2023, then surged by 44bps to 2.01% in 2024, then soared by 37bps to 1.26% in 2025.
  • Business Quant data shows Return on Equity for TCRT at 1.26% in Q3 2025, 1.71% in Q2 2025, and 2.67% in Q1 2025.